Adaptive TCR Corp
Adaptive TCR Corp is listed today as Adaptive Biotechnologies Corporation: market value, financials and filings are on its company page.
Funding rounds
7 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2015 | $195 M | No. 7 | $50 to $250 million | equity | SEC | |
| Jan 2015 | $94 M | No. 6 | $50 to $250 million | equity | SEC | |
| Apr 2014 | $107 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jul 2013 | $5 M | No. 4 | $2 to $10 million | equity | SEC | |
| Jun 2012 | $3 M | No. 3 | $2 to $10 million | equity | SEC | |
| May 2011 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Dec 2009 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Adaptive Biotechnologies Corporation, its revenue in fiscal 2025 came from these product and service lines: Immune Medicine Service Revenue $41.30 million (15%).
Annual report (SEC XBRL) · Dec 2025
Adaptive TCR Corp chose not to state its revenue in its newest notice of a funding round (May 2015).
SEC Form D · May 2015
The industry group it chose in its notices: Other.
SEC Form D · May 2015
Products and services#
No products or services of Adaptive TCR Corp are on record.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Andris A. Zoltners | Person | not stated | not stated | Held Series A, B, C, E-1 and F preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Chad M. Robins | Person | not stated | not stated | Held Series E-1 preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Harlan S. Robins | Person | not stated | not stated | Held Series E-1 preferred stock (Form 3, 2019) | SEC Form 3 |
| Matrix Capital Management Company, LP | Fund or asset manager | not stated | not stated | Held Series A, E-1, F and F-1 preferred (Form 3, 2019) | SEC Form 3 |
| VGE III Portfolio Ltd. | Company | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Equities II LP | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Equities LP | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Equities Master Ltd. | Company | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Investors LP | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Opportunities GP LLC | Other | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Opportunities Portfolio GP LLC | Other | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Global Performance LLC | Other | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Long Fund GP LLC | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Viking Long Fund Master Ltd. | Fund or asset manager | not stated | not stated | Held Series D, E, F and F-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 63 investors.
Largest shareholders today
Institutions holding Adaptive Biotechnologies Corporation shares, as of Sep 30, 2026.
- Viking Global Investors LP$867 M18.53%
- BlackRock, Inc.$442 M9.45%
- Vanguard Capital Management LLC$186 M3.98%
- D. E. Shaw & Co., Inc.$184 M3.94%
- Price T Rowe Associates Inc /MD/$165 M3.52%
- Vanguard Portfolio Management LLC$151 M3.24%
- Wellington Management Group LLP$137 M2.93%
- Driehaus Capital Management LLC$136 M2.91%
- Geode Capital Management, LLC$108 M2.30%
- T. Rowe Price Investment Management, Inc.$104 M2.22%
- State Street Corp$103 M2.20%
- Lord, Abbett & Co. LLC$96 M2.05%
- Invesco Ltd.$93 M1.99%
- Goldman Sachs Group Inc$89 M1.91%
- Principal Financial Group Inc$71 M1.51%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chad Robins | Executive officer | May 2015 |
| Dean Schorno | Executive officer | May 2015 |
| Kathleen Determann | Executive officer | May 2015 |
| Chris Carlson | Executive officer | Aug 2014 |
| Harlan Robins | Executive officer | Aug 2014 |
| Andris Zoltners | Director | May 2015 |
| Arnold Levine | Director | May 2015 |
| Chad Cohen | Director | May 2015 |
| Chad Robins | Director | May 2015 |
| John Stuelpnagel | Director | May 2015 |
| Peter Neupert | Director | May 2015 |
| Rob Hershberg | Director | May 2015 |
| Rob Rosen | Director | May 2015 |
| Tom Willis | Director | May 2015 |
| Lee Huntsman | Director | Jan 2015 |
| Andy Zoltners | Director | Jun 2012 |
| Craig Weissman | Director | Jun 2012 |
| Harlan Robins | Director | Dec 2009 |
About
Company in Seattle, United States.
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.